Cycle Pharmaceuticals Sticks to $488 Million Offer for Vanda Pharmaceuticals

Cycle Pharmaceuticals is reportedly holding firm on its substantial offer of $488 million for Vanda Pharmaceuticals, aiming to expand its portfolio with the acquisition of this biopharmaceutical player. The proposed bid highlights Cycle's strategic interest in Vanda, especially considering the latter's promising product pipeline.

Continue reading